<DOC>
	<DOCNO>NCT02604407</DOCNO>
	<brief_summary>The study design evaluate efficacy safety dose SHP465 ( 12.5 37.5 mg ) give participant daily morning compare placebo treatment adult age 18 55 year diagnose ADHD .</brief_summary>
	<brief_title>Safety Efficacy Study SHP465 Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Subject must 1855 year age Subject able provide write , personally sign date informed consent . Subject willing able comply test requirement define protocol Subject , female , must pregnant . Subject must satisfactory medical assessment clinically significant relevant abnormality . Subject primary diagnosis ADHD . Subject adult ADHDRS prompt total score ≥28 baseline visit . Subject must minimum level intellectual functioning , determine investigator . Subject able swallow capsule . Subject currently ADHD therapy completely satisfy aspect current ADHD therapy . Subject current , comorbid psychiatric diagnosis significant symptom . Subject consider suicide risk opinion investigator Subject body mass index ( BMI ) &lt; 18.5 kg/m2 screen visit . Subject BMI ≥40 kg/m2 screen visit . Subject concurrent chronic acute illness , disability , condition . Subject history seizure , chronic current tic disorder , current diagnosis Tourette 's disorder . Subject history moderate severe hypertension . Subject known history symptomatic cardiovascular disease Subject know family history sudden cardiac death ventricular arrhythmia . Subject clinically significant ECG clinically significant laboratory abnormality screen visit . Subject current abnormal thyroid function Subject document allergy , hypersensitivity , intolerance amphetamine excipients investigational product . Subject fail respond , adequate course ( ) amphetamine therapy . Subject history suspect substance abuse dependence disorder . Subject positive urine drug result screen visit ( exception subject 's current stimulant therapy , ) Subject take another investigational product take part clinical study within 30 day prior screen visit . Subject previously complete , discontinue , withdrawn study . Subject take medication exclude appropriately wash accord protocol requirement . Subject required take anticipates need take medication CNS effect affect performance . Subject female pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>